NYSE:TGX 90562 Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding 90562 Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2,160 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsHeadlinesSEC FilingsSocial Media Theragenics Corporation is a medical device company serving the surgical products and cancer treatment markets. The Company operates in two business segments: surgical products segment and brachytherapy seed segment. The Company's surgical products business manufactures, markets and sells disposable devices primarily utilized in certain surgical procedures. The Company's brachytherapy seed business manufactures, markets and sells radioactive seeds primarily utilized in the treatment of early stage prostate cancer. The Company designs , manufactures, assembles, packages and distributes its surgical products in three primary production facilities, each of which manufactures different products. In October 2013, the Company announced that it has completed the merger with Juniper Acquisition Corporation.Read More MarketRank™Overall MarketRank™0.52 out of 5 starsAnalyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for 90562. Previous Next 2.6 Community Rank Outperform Votes90562 has received 50 “outperform” votes. (Add your “outperform” vote.)Underperform Votes90562 has received 46 “underperform” votes. (Add your “underperform” vote.)Community Sentiment90562 has received 52.08% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about 90562 and other stocks. Vote “Outperform” if you believe TGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TGX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend Yield90562 does not currently pay a dividend.Dividend Growth90562 does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 90562 insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here Industry, Sector and Symbol Stock Exchange NYSE Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNYSE:TGX Previous Symbol CUSIPN/A CIK795551 Webwww.theragenics.com Phone+1-770-8315137EmployeesN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive TGX News and Ratings via Email Sign-up to receive the latest news and ratings for TGX and its competitors with MarketBeat's FREE daily newsletter. 90562 (NYSE:TGX) Frequently Asked Questions What stocks does MarketBeat like better than 90562? Wall Street analysts have given 90562 a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 90562 wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. What is Larry J. Merlo's approval rating as 90562's CEO? 6,978 employees have rated 90562 CEO Larry J. Merlo on Glassdoor.com. Larry J. Merlo has an approval rating of 37% among 90562's employees. This puts Larry J. Merlo in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of 90562 own? Based on aggregate information from My MarketBeat watchlists, some companies that other 90562 investors own include (APHA), Hologic (HOLX), Eldorado Gold (EGO), (CGC) and Bombardier, Inc. Class B (BBD.B). What is 90562's stock symbol? 90562 trades on the New York Stock Exchange (NYSE) under the ticker symbol "TGX." What is 90562's official website? The official website for 90562 is www.theragenics.com. How can I contact 90562? 90562's mailing address is 5203 Bristol Industrial Way, BUFORD, GA 30518, United States. The medical device company can be reached via phone at +1-770-8315137. This page was last updated on 1/22/2021 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here